Publications by authors named "Elisabetta Fenu"
Background: Current therapies for complex Crohn's perianal fistulas (CPF) have a limited ability to achieve long-term healing. Darvadstrocel (DVS) is an expanded allogeneic adipose-derived mesenchymal stem cell therapy that has demonstrated efficacy in treating complex CPF in clinical trials. There are, however, limited long-term comparative data with standard of care (SoC).
View Article and Find Full Text PDFThis study evaluated the cost-effectiveness of maribavir versus investigator-assigned therapy (IAT; valganciclovir/ganciclovir, foscarnet, or cidofovir) for post-transplant refractory cytomegalovirus (CMV) infection with or without resistance. A two-stage Markov model was designed using data from the SOLSTICE trial (NCT02931539), real-world multinational observational studies, and published literature. Stage 1 (0-78 weeks) comprised clinically significant CMV (csCMV), non-clinically significant CMV (n-csCMV), and dead states; stage 2 (78 weeks-lifetime) comprised alive and dead states.
View Article and Find Full Text PDFArticle Synopsis
- Inflammatory bowel disease (IBD) leads to significant social and economic challenges, prompting an analysis of the budget impact of using a new subcutaneous formulation of vedolizumab for maintaining ulcerative colitis (UC) treatment in France.
- A decision-analytic model was created to compare the costs of including vedolizumab SC as maintenance therapy against existing treatment options, predicting total drug, medical, and indirect costs over a five-year period.
- Results showed that incorporating vedolizumab SC could save over €59 million for biologic-naïve patients and nearly €22 million for those already on biologics, indicating strong financial benefits for French health plans.
Article Synopsis
- Ulcerative colitis is a common condition in Canada, necessitating the exploration of affordable treatment options; the study evaluates the cost-effectiveness of the newly approved subcutaneous vedolizumab compared to various other therapies from a Canadian healthcare payer's perspective.* -
- A decision tree/Markov model was used to analyze costs, quality-adjusted life-years (QALYs), and treatment effectiveness for vedolizumab SC against several established therapies, accounting for uncertainties and varying treatment scenarios.* -
- Results indicated that while conventional therapy was the most cost-effective overall, vedolizumab SC was a cost-effective and leading option when compared to other advanced treatments, offering significant savings and achieving the highest QALYs among
Background: Domestic violence and abuse (DVA) damages the health of survivors and increases use of healthcare services. We report findings from a multi-site evaluation of hospital-based advocacy services, designed to support survivors attending emergency departments and maternity services.
Methods: Independent Domestic Violence Advisors (IDVA) were co-located in five UK hospitals.
Introduction: This study sought to determine the cost-effectiveness of intravitreal ranibizumab compared with best supportive care (BSC; considered to be no active treatment) for the treatment of visual impairment due to choroidal neovascularization (CNV) associated with causes other than neovascular age-related macular degeneration (nAMD) and pathologic myopia (PM) in a UK setting.
Methods: An individual patient-level simulation model was developed to estimate the lifetime costs and quality-adjusted life years (QALYs) of ranibizumab vs. BSC.
Objectives: To assess the cost-effectiveness of basal insulin regimens for adults with type 1 diabetes mellitus in England.
Methods: A cost-utility analysis was conducted in accordance with the National Institute for Health and Care Excellence reference case. The UK National Health Service and personal and social services perspective was used and a 3.
Background: Seven drugs are licensed for the treatment of chronic hepatitis B (CHB) in the United Kingdom. Which initial treatment, secondary therapy, and whether antivirals should be given alone or in combination are questions of considerable uncertainty.
Objective: The aim of this model was to undertake a comprehensive economic evaluation of all antiviral treatments for CHB to recommend the most cost-effective therapeutic sequence.
The National Clinical Guideline Centre (NCGC) develops evidence-based clinical guidelines on behalf of the National Institute for Health and Clinical Excellence (NICE) in the United Kingdom. The U.K.
View Article and Find Full Text PDF